Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De Sells 2,347 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 2,347 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $9.47, for a total value of $22,226.09. Following the completion of the sale, the executive vice president now owns 61,370 shares in the company, valued at approximately $581,173.90. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Verneuil Vanina De also recently made the following trade(s):

• On Friday, November 1st, Verneuil Vanina De sold 1,403 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.20, for a total value of $10,101.60.

Vir Biotechnology Trading Up 2.9 %

Shares of VIR stock traded up $0.27 during trading hours on Tuesday, reaching $9.64. The stock had a trading volume of 1,110,639 shares, compared to its average volume of 1,024,860. The stock’s fifty day simple moving average is $7.77 and its 200 day simple moving average is $8.88. The firm has a market capitalization of $1.32 billion, a PE ratio of -2.46 and a beta of 0.46. Vir Biotechnology, Inc. has a 12 month low of $7.12 and a 12 month high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The firm had revenue of $2.38 million for the quarter, compared to analysts’ expectations of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm’s revenue for the quarter was down 9.8% on a year-over-year basis. During the same quarter last year, the firm earned ($1.22) earnings per share. As a group, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.26 EPS for the current fiscal year.

Institutional Trading of Vir Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Vir Biotechnology by 0.6% in the first quarter. Vanguard Group Inc. now owns 12,375,355 shares of the company’s stock valued at $125,362,000 after acquiring an additional 78,216 shares during the last quarter. Millennium Management LLC lifted its position in Vir Biotechnology by 94.6% in the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock worth $11,108,000 after buying an additional 606,804 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Vir Biotechnology by 0.8% in the second quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock worth $7,238,000 after buying an additional 6,359 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Vir Biotechnology by 10.1% during the second quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after acquiring an additional 58,360 shares in the last quarter. Finally, Empowered Funds LLC lifted its holdings in shares of Vir Biotechnology by 8.2% in the 1st quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock worth $4,640,000 after acquiring an additional 34,640 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Barclays cut their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a report on Monday. Finally, Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a report on Friday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $36.40.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).